Epoetin alfa (Eprex) for anaemia in adults with low or intermediate-1 risk myelodysplastic syndromes
NIHR HSRIC
Record ID 32016000814
English
Authors' recommendations:
Myelodysplastic syndromes are a group of rare diseases which affect the bone marrow – the part of the body where blood cells are made. In myelodysplastic syndromes, the bone marrow does not make enough healthy blood cells. This causes symptoms such as feeling weak, tired and breathless due to lack of red blood cells (anaemia).
Epoetin alfa is a drug not currently licensed but already used for the treatment of anaemia in adults with myelodysplastic syndromes that is injected under the skin. If epoetin alfa is licensed for use in the UK, it would be the first drug specifically for these patients, and could improve their quality of life.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/epoetin-alfa-eprex-for-anaemia-in-adults-with-low-or-intermediate-1-risk-myelodysplastic-syndromes/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Adult
- Epoetin Alfa
- Erythropoietin
- Anemia
- Myelodysplastic Syndromes
- Risk
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.